Varivax Injection, Powder, Lyophilized, For Suspension
NDC Package 0006-4827-00

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Varivax (varicella virus vaccine live) injection is vARIVAX® is a vaccine indicated for active immunization for the prevention of varicella in individuals 12 months of age and older. This formulation utilizes a injection, powder, lyophilized, for suspension delivery system. Marketed by Merck Sharp & Dohme Llc, this product is identified by NDC 0006-4827 and is authorized under FDA application BLA103552.

Identification & Billing

NDC Package Code
0006-4827-00
Package Description
10 VIAL, SINGLE-DOSE in 1 CARTON / .5 mL in 1 VIAL, SINGLE-DOSE (0006-4827-01)
Product Code
0006-4827
11-Digit Billing Format
00006482700
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk
  • RxCUI: 1292457 - varicella virus vaccine live (VAR) 1350 PFU in 0.5 ML Injection
  • RxCUI: 1292457 - 0.5 ML varicella-zoster virus vaccine live (Oka-Merck) strain 2700 UNT/ML Injection
  • RxCUI: 1292457 - varicella-zoster virus vaccine live (Oka-Merck) strain 1350 PFU per 0.5 ML Injection
  • RxCUI: 1292459 - VARIVAX vaccine 0.5 ML Injection
  • RxCUI: 1292459 - 0.5 ML varicella-zoster virus vaccine live (Oka-Merck) strain 2700 UNT/ML Injection [Varivax]

Clinical Specifications

Proprietary Name
Varivax
Non-Proprietary Name
Varicella Virus Vaccine Live
Substance Name
Varicella-zoster Virus Strain Oka/merck Live Antigen
Dosage Form
Injection, Powder, Lyophilized, For Suspension - A liquid preparation, intended for parenteral use that contains solids suspended in a suitable fluid medium and conforms in all respects to the requirements for Sterile Suspensions; the medicinal agents intended for the suspension are prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN 1350 [PFU]/.5mL
Pharmacologic Class
Usage Information
VARIVAX® is a vaccine indicated for active immunization for the prevention of varicella in individuals 12 months of age and older.

Regulatory & Marketing

Labeler Name
Merck Sharp & Dohme Llc
Product Type
Vaccine
FDA Application #
BLA103552
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
03-17-1995
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0006-4827-00 identifies a specific commercial package of 10 vial, single-dose in 1 carton / .5 ml in 1 vial, single-dose (0006-4827-01) of Varivax, a vaccine label labeled by Merck Sharp & Dohme Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This injection, powder, lyophilized, for suspension is formulated for subcutaneous use and contains varicella-zoster virus strain oka/merck live antigen as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Merck Sharp & Dohme Llc on March 17, 1995. The current certification is valid through December 31, 2026.

How is this Merck Sharp & Dohme Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00006482700. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0006-4827-00
11-Digit CMS (5-4-2)
00006-4827-00

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.